Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?
Frank L
FL
Meyskens
Christine E
CE
McLaren
D000236:Adenoma / Q000517:prevention & control; D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000517:prevention & control; D002280:Basal Cell Carcinoma / Q000517:prevention & control; D002294:Carcinoma, Squamous Cell / Q000517:prevention & control; D000068579:Celecoxib; D018890:Chemoprevention / Q000639:trends*; D015179:Colorectal Neoplasms / Q000517:prevention & control; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D005260:Female; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009369:Neoplasms / Q000517:prevention & control*; D011315:Preventive Medicine / Q000639:trends*; D011471:Prostatic Neoplasms / Q000517:prevention & control; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D040242:Risk Reduction Behavior; D012878:Skin Neoplasms / Q000517:prevention & control; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects; D009626:Terminology as Topic
D016588:Anticarcinogenic Agents; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib